Skip to main content
. 2017 Apr 6;8(31):50655–50664. doi: 10.18632/oncotarget.16901

Figure 6. Usp5 promoted drug resistance in HepG2 cells.

Figure 6

(A and B) Usp5 knockdown suppressed the viabilities in HepG2 cells (A) and Bel7404 cells (B) with 2.0 μM Dox and 10 μM Cis treatment. (C and D) Usp5 overexpression promoted cell growth in the Dox and Cis treated HepG2 cells (C) and Bel7404 cells (D). **P < 0.01.